Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06439966 | Expanded Access to ABBV-787 | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT00590915 | Erwinase Master Treatment Protocol(EMTP) | no longer available | — | — | Phoenix Children's HospitalOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT05215405 |
| Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL |
| no longer available |
| — |
| — |
| Kathleen LudwigOTHER |
| 1 |
| Feb 3, 2025 |
| clinicaltrials |
| NCT03420430 | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | no longer available | — | — | Genelux CorporationINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05219266 | Managed Access Programs for PKC412, Midostaurin | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 28, 2024 | clinicaltrials |
| NCT03592576 | Expanded Access to Navitoclax | no longer available | — | — | AbbVieINDUSTRY | 0 | May 6, 2024 | clinicaltrials |
| NCT04559555 | MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 9, 2022 | clinicaltrials |
| NCT04678466 | Flotetuzumab Expanded Access Program | no longer available | — | — | MacroGenicsINDUSTRY | 0 | May 31, 2022 | clinicaltrials |
| NCT02258490 | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | no longer available | — | — | Emory UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT03594162 | Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01200017 | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | no longer available | — | — | Christopher DvorakOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT03723057 | Expanded Access for AG-221 | no longer available | — | — | CelgeneINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT03409081 | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | no longer available | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 13, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials